Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18615120 | 0.81 | MAPT (0.50) | MAPTCYP1A2POLBRXFP1MEN1 | |
| SCHEMBL2252622 | 0.80 | MAPT (0.48) | MAPTCYP1A2NPC1RAB9ANPSR1 | |
| SCHEMBL1691036 | 0.78 | MAPT (0.51) | MAPTCYP1A2PKMEGFRNPC1 | |
| SCHEMBL30587541 | 0.78 | MAPT (0.51) | MAPTCYP1A2PKMEGFRNPC1 | |
| SCHEMBL13868451 | 0.77 | MAPT (0.47) | MAPTCYP1A2PKMEGFRNPC1 | |
| SCHEMBL12317134 | 0.76 | KMT2A (0.59) | MAPTCYP1A2NPC1RAB9ARXFP1 | |
| SCHEMBL31636731 | 0.75 | MAPT (0.44) | MAPTEGFRNPC1POLBRAB9A | |
| SCHEMBL11753228 | 0.75 | MAPT (0.57) | MAPTCYP1A2POLBCYP2C19SMN1; SMN2 | |
| SCHEMBL12317142 | 0.74 | MAPT (0.50) | MAPTCYP1A2PKMNPC1RAB9A | |
| SCHEMBL18952565 | 0.74 | MAPT (0.39) | MAPTCYP1A2NPC1POLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2536710-B1 | PIPERIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2016-07-13 | — | — | EP | disclosed |
| US-8486967-B2 | Heteroaryl substituted piperidines | HOFFMANN-LA ROCHE INC. (US) | 2013-07-16 | — | — | US | disclosed |
| EP-2536710-A2 | PIPERIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-12-26 | — | — | EP | disclosed |
| EP-2531503-A1 | GAMMA SECRETASE MODULATERS | F. Hoffmann-La Roche AG (CH) | 2012-12-12 | — | — | EP | disclosed |
| WO-2011101304-A2 | PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-25 | — | — | WO | disclosed |
| US-20110201605-A1 | HETEROARYL SUBSTITUTED PIPERIDINES | HOFFMANN-LA ROCHE, INC. | 2011-08-18 | — | — | US | disclosed |
| WO-2011092272-A1 | GAMMA SECRETASE MODULATERS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-04 | — | — | WO | disclosed |
| US-20110190269-A1 | GAMMA SECRETASE MODULATORS | HOFFMANN-LA ROCHE, INC. | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190269-A1 | GAMMA SECRETASE MODULATORS | BACE1, APH1A, APH1B | MAPT 575/4885CYP1A2 1838/4885PKM 4471/4885 |
| US-20110201605-A1 | HETEROARYL SUBSTITUTED PIPERIDINES | APP, HPGDS, PSEN1 | MAPT 582/4885CYP1A2 1317/4885PKM 3059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.